ClinicalTrials.Veeva

Menu

Comparing Hemodiafiltration with and Without Hemoadsorption

H

Hospital Clinic of Barcelona

Status

Completed

Conditions

Hemodialysis
Hemoadsorption
Hemodiafiltration

Treatments

Device: Hemoadsorption cartridge
Device: Hemodiafiltration

Study type

Interventional

Funder types

Other

Identifiers

NCT06710834
HCB/2024/0704

Details and patient eligibility

About

Goals: The aim of the study is to assess the efficacy and safety of the combination of HDF + HA compared to HDF. To do this, we will evaluate the elimination of a wide range of molecular weight molecules, including small protein-bound solutes.

Design: Prospective, single-center study. Each patient underwent two dialysis sessions with routine dialysis parameters in which HDF or HDF + HA treatment modality will be compared.

Study subjects: 20 patients, stable on a thrice-weekly hemodialysis program, will be included. Local Ethics Committee will approve the study and patients will give informed consent.

Interventions: Prospective collection of two dialysis sessions. The only difference among the sessions in each patient will be add or no sorbent cartridge. One session with FX60 Cordiax, helixone, Fresenius Medical Care in postdilution on-line hemodiafiltration and another session with the same dialyzer plus HA 130 cartridge. The order of these treatment sessions was randomly. Blood samples for analyses were taken for each patient in the same dialysis session of the week.

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  • Adult patients (age > 18 years)
  • More than 6 months on a dialysis program
  • Stable in a hemodialysis program
  • AV fistula, prosthesis, or tunneled catheter as vascular access
  • No residual diuresis (< 200 ml/day)
  • Not enrolled in a living donor transplant program
  • No immunosuppressive treatment
  • Provide written informed consent

Exclusion Criteria

  • Chronic inflammatory diseases
  • Neoplasms
  • Immunosuppressive treatment or chronic treatment with anti-inflammatory drugs
  • Dysfunctional AV fistula or catheter
  • Single-needle dialysis
  • Kt/V less than 1.3 or PRU < 70%
  • Scheduled living donor kidney transplant

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

20 participants in 2 patient groups

Hemodiafiltration alone
Active Comparator group
Treatment:
Device: Hemodiafiltration
Hemodiafiltration plus hemoadsorption
Experimental group
Treatment:
Device: Hemodiafiltration
Device: Hemoadsorption cartridge

Trial contacts and locations

1

Loading...

Central trial contact

Francisco Maduell, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems